Bayer has opened its manufacturing site of traditional Chinese medicine (TCM) and Western medicines in the Majinpu bioengineering and pharmaceutical industrial park in Yunnan, China. The site is Bayer's second largest over-the-counter (OTC) manufacturing facility in Asia Pacific.

The facility covers an area of 111,534 square meters. Stage 1 of Phase I construction gained the GMP certificate for its partial TCM production line. Upgrading work is ongoing, which will be put into production for Bayer's key TCM product, DEFK. 

The construction of the Majinpu site was started in 2013 by Dihon and was taken over by Bayer after its acquisition of Dihon in November 2014.

The site consolidates Bayer's TCM supply capabilities in Yunnan. It will boost its manufacturing capacity for TCM products three-fold in 2016 and will also triple the manufacturing and supplying capacity for all Dihon products by 2020. By 2020, the total estimated investment in the facility will amount to CNY 1.4 billion ($213 million).

Source: Bayer